Christopher Van Tuyl compensation by year
Immunovant Summary Compensation Table · all 2 fiscal years held| Component | FY2025 | FY2026 |
|---|---|---|
| Salary | $140,292 | $495,000 |
| Bonus | $62,860 | $245,025 |
| Stock awards | $3,038,084 | $771,962 |
| Option awards | $2,699,742 | $766,726 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $7,361 | $17,064 |
| Total | $5,948,339 | $2,295,777 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunovant, Inc. DEF 14A filed July 22, 2026, accession 0001764013-26-000092, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Immunovant, Inc. filed document, accession 0001764013-26-000092. Every figure is read from that document and cited to the page and table it appears in. Filed July 22, 2026.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 75,595 | $1,877,780 | — |
| RSU | 50,787 | $1,261,549 | — |
| Option | 71,531 | — | $15.20 |
| Option | 94,494 | — | $27.63 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Immunovant, Inc.'s FY2026 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2026 proxy (filed July 22, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-07 | Sale | — | 1,327 | $32.06 | 175,218 |
| 2026-09-23 | Sale | — | 2,846 | $36.36 | 176,545 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Immunovant discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | — | $0 | — | — |
| Change in control and involuntary termination | — | $1,879,148 | — | — |
| Change in control and resignation for good reason | — | $1,879,148 | — | — |
| Resignation for good reason, no change in control | — | $0 | — | — |
Per the Potential Payments Upon Termination or Change in Control table in Immunovant, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Immunovant’s named executive officers, FY2026
as the company reported each| Named executive officer | Role | FY2026 total |
|---|---|---|
| Eric Venker | Chief Executive Officer | $20,158,767 |
| Peter Salzmann | Former Chief Executive Officer | $15,334,600 |
| Tiago Girão | Chief Financial Officer | $7,616,437 |
| Michael Geffner | Former Chief Medical Officer | $5,254,089 |
| Eva Renee Barnett | Former Chief Financial Officer | $3,227,452 |
| Melanie Gloria | Chief Operating Officer | $3,067,112 |
| Jay Stout | Chief Technology Officer | $3,065,721 |
| Christopher Van Tuyl · this page | Chief Legal Officer and Corporate Secretary | $2,295,777 |
Christopher Van Tuyl's compensation dossier, Immunovant
You have read Christopher Van Tuyl's totals and holdings. The dossier adds each equity grant Immunovant disclosed for Christopher Van Tuyl and Immunovant's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Immunovant compensation record
free company briefThis page is one person within Immunovant's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Immunovant proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Immunovant's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunovant's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order IMVT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.